Welcome to our dedicated page for Plus Therapeutics news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on Plus Therapeutics stock.
Plus Therapeutics Inc (NASDAQ: PSTV) is a clinical-stage biopharmaceutical company pioneering targeted radiotherapeutics for challenging cancers. This news hub provides investors and medical professionals with essential updates on clinical trials, regulatory developments, and strategic partnerships.
Access timely reports on PSTV's innovative CNS cancer therapies including rhenium (186Re) obisbemeda for glioblastoma and leptomeningeal metastases. Track progress across multiple development stages while staying informed about financial updates and manufacturing collaborations that support the company's pipeline.
Our curated collection features earnings announcements, trial result disclosures, FDA communications, and partnership expansions. All content is verified through primary sources to ensure accuracy for investment research and clinical practice decisions.
Bookmark this page for streamlined access to PSTV's latest scientific advancements and corporate developments. Check regularly for critical updates impacting the neuro-oncology treatment landscape and the company's position within precision radiotherapy markets.
Plus Therapeutics (PSTV) reported financial results for Q4 and full year 2021, showing a net loss of $13.4 million, or $(1.11) per share, compared to $8.2 million, or $(1.86) per share, in 2020. The company raised $28.5 million to strengthen its balance sheet, with cash balances at $23 million as of January 31, 2022. Notable advancements include positive interim data from the ReSPECT-GBM Phase 1/2 trial of 186RNL, plans for a Phase 2 trial in 2022, and FDA Fast Track designation for 186RNL in treating leptomeningeal metastases.
Plus Therapeutics (PSTV) announced a partnership with Medidata to evaluate the Synthetic Control Arm (SCA) in a planned Phase 2 trial for Rhenium-186 NanoLiposome (186RNL) targeting recurrent glioblastoma. SCAs may improve patient enrollment and retention by using historical data to create control groups, thereby potentially lowering trial costs while maintaining scientific integrity. The FDA has recognized a Phase 3 trial design using synthetic controls, indicating a positive regulatory outlook for innovative trial methodologies.
Plus Therapeutics, Inc. (PSTV) will release its fourth quarter and full year 2021 financial results on February 24, 2022, after market close. Following the announcement, a conference call will be held at 5:00 p.m. ET to discuss the results and provide a corporate update. The call will be accessible via a live webcast on the company's investor relations page. Plus Therapeutics develops innovative radiotherapeutics for hard-to-treat cancers and is evaluating its lead product, Rhenium-186 NanoLiposome, in clinical trials.
Plus Therapeutics (Nasdaq: PSTV) announced that Marc H. Hedrick M.D., President and CEO, will present at the BIO CEO & Investor Conference on February 14, 2022, at 1:15 p.m. ET in New York City. The presentation will provide an overview of the company's innovative radiotherapeutics for rare cancers, focusing on their lead product, Rhenium-186 NanoLiposome, currently evaluated in clinical trials for treating recurrent glioblastoma. The live presentation can be accessed by registered participants via the conference website.
AUSTIN, Texas, Jan. 07, 2022 - Plus Therapeutics (Nasdaq: PSTV) announced that Marc H. Hedrick, M.D., will speak at two virtual conferences this January. The H.C. Wainwright BioConnect Conference will take place from January 10-13, with presentations available on demand starting January 10 at 7:00 a.m. ET. Additionally, the Biotech Showcase 2022 is scheduled for January 10-12 and 17-19, with on-demand access for presentations. Webcast replays and further information can be found on their website.
Plus Therapeutics has secured a worldwide exclusive license from UT Health San Antonio to develop innovative interventional radiotherapeutics for solid organ cancers. This deal enhances their proprietary Rhenium NanoLiposome technology, aiming to deliver targeted cancer therapies, specifically for liver cancer. The licensed technology includes biodegradable alginate microspheres to block blood flow to tumors while delivering high doses of cytotoxic compounds. An IND submission for liver cancer treatment is planned for 2022, tapping into a $1.3 billion market opportunity.
Plus Therapeutics (PSTV) has achieved key milestones in developing Rhenium-186 NanoLiposome (186RNL) radiotherapeutic. The company signed a master services agreement with IsoTherapeutics Group for cGMP grade Rhenium-186 isotope manufacturing, ensuring compliance with FDA standards for clinical trials. This agreement is expected to facilitate future clinical and commercial supply contracts. Furthermore, Plus Therapeutics has transferred analytical test methods to Piramal Pharma Solutions, paving the way for the cGMP drug product intermediate manufacturing, crucial for ongoing trials targeting difficult-to-treat cancers.
Plus Therapeutics (Nasdaq: PSTV) announced that Marc H. Hedrick, M.D., President & CEO, will present at the MedInvest Oncology Investor Conference on December 7, 2021, at 12:00 p.m. ET. The presentation will cover the company's innovative radiotherapeutics for rare cancers. A pre-recorded webcast of the presentation and a live Q&A will be available on the company's Investor Relations page. Plus Therapeutics focuses on developing advanced cancer treatments using novel liposomal encapsulation technology aimed at enhancing drug delivery and patient outcomes.
Plus Therapeutics (PSTV) has reported positive interim results from its Phase 1 ReSPECT™-GBM clinical trial, focusing on the investigational drug Rhenium-186 NanoLiposome (186RNL) for recurrent glioblastoma (GBM). The study revealed it is well-tolerated with no dose-limiting toxicities. Patients receiving more than 100 Gy of radiation experienced a mean overall survival of 453.8 days. The trial has evaluated 22 patients over six years, and significant delivery parameters were noted, supporting further clinical investigations.
Plus Therapeutics, Inc. (PSTV) announced the granting of option awards to Dr. Norman LaFrance on November 11, 2021, as part of his induction as Chief Medical Officer. The awards include options to purchase up to 120,000 shares of common stock, vesting over four years with specific conditions related to Dr. LaFrance's continued service. This move aims to align his interests with those of the shareholders. The options were granted outside of the company's 2020 Incentive Plan but follow similar terms. Plus Therapeutics is focused on innovative treatments for cancer.
FAQ
What is the current stock price of Plus Therapeutics (PSTV)?
What is the market cap of Plus Therapeutics (PSTV)?
